Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Inclusion Criteria:

   - Patients with lung nodule or mass concerning for malignancy, either primary lung
   cancer or lung metastases, whether or not it is biopsy-proven

   - Patients scheduled to undergo planned standard of care surgical resection for a lung
   nodule or mass with diagnostic and/or curative intent for lung cancer

   - Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group
   (ECOG)/Zubrod level 0-2

   - Hemoglobin ≥ 9 gm/dL

   - White blood cell count > 3000/mm^3

   - Platelet count ≥ 100,000/mm^3

   - Serum creatinine ≤ 1.5 times upper reference range

Exclusion Criteria:

   - Received an investigational drug within 30 days prior to first dose of
   panitumumab-IRDye800

   - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
   heart failure (CHF); significant liver disease; or unstable angina within 6 months
   prior to enrollment

   - History of infusion reactions to monoclonal antibody therapies

   - Pregnant or breastfeeding

   - Magnesium or potassium lower than the normal institutional values

   - Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide,
   amiodarone, sotalol) antiarrhythmic agents

   - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis

   - Prisoners, institutionalized individuals, and patients unable to consent for
   themselves